Back off to better blow up: acute GFR decrease at SGLT-2 inhibitor initiation.
other · Level V
Where this comes from
- Record sourced from PubMed, PMID 33745548.
- Also identified by DOI 10.1016/j.kint.2020.12.033.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The drop in glomerular filtration rate often observed in the first weeks of nephroprotective treatment, whether because of protein restriction or renin-angiotensin system blockade, can be interpreted as a marker of the relationship between the intensity of baseline glomerular anomalies and the potential treatment benefit. In this issue, Oshima et al. reported a post hoc analysis of the Canagliflozin and Renal Events in Diabetes With Established Nephropathy Clinical Evaluation (CREDENCE) study, the results of which confirm that such a relationship is also observed under sodium-glucose cotransporter 2 inhibition in diabetic patients with chronic kidney disease.
Medical subject headings
- Diabetes Mellitus, Type 2
- Renal Insufficiency, Chronic
- Sodium-Glucose Transporter 2 Inhibitors